董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Maykin Ho | 女 | Director | 73 | 未披露 | 未持股 | 2026-01-19 |
| Willard Dere | 男 | Director | 72 | 64.87万美元 | 未持股 | 2026-01-19 |
| Barbara W. Bodem | 女 | Director | 58 | 未披露 | 未持股 | 2026-01-19 |
| Elizabeth McKee Anderson | 女 | Director | 68 | 未披露 | 未持股 | 2026-01-19 |
| Alexander Hardy | 男 | Director,President and Chief Executive Officer | 57 | 未披露 | 未持股 | 2026-01-19 |
| Ian T. Clark | -- | Director | -- | 未披露 | 未持股 | 2026-01-19 |
| Robert J. Hombach | 男 | Director | 60 | 未披露 | 未持股 | 2026-01-19 |
| Richard A. Meier | 男 | Chair and Director | 66 | 44.30万美元 | 未持股 | 2026-01-19 |
| Timothy P. Walbert | 男 | Director | 59 | 未披露 | 未持股 | 2026-01-19 |
| Athena Countouriotis | 女 | Director | 54 | 未披露 | 未持股 | 2026-01-19 |
| Mark J. Enyedy | 男 | Director | 62 | 未披露 | 未持股 | 2026-01-19 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Alexander Hardy | 男 | Director,President and Chief Executive Officer | 57 | 未披露 | 未持股 | 2026-01-19 |
| Gregory R. Friberg | 男 | Executive Vice President and Chief Research & Development Officer | 52 | 未披露 | 未持股 | 2026-01-19 |
| C. Greg Guyer | -- | Executive Vice President and Chief Technical Officer | 64 | 未披露 | 未持股 | 2026-01-19 |
| Cristin Hubbard | 女 | Executive Vice President and Chief Commercial Officer | 50 | 未披露 | 未持股 | 2026-01-19 |
| Rashmi Ramchandani | 女 | Vice President and Chief Accounting Officer | 47 | 未披露 | 未持股 | 2026-01-19 |
| G. Eric Davis | 男 | Executive Vice President, Chief Legal Officer and Secretary | 55 | 270.82万美元 | 未持股 | 2026-01-19 |
| Brian R. Mueller | 男 | Executive Vice President and Chief Financial Officer | 52 | 未披露 | 未持股 | 2026-01-19 |
董事简历
中英对照 | 中文 | 英文- Maykin Ho
-
Maykin Ho，2015年8月起担任董事，也是审计及财务委员会的成员。她自2015年7月起担任Qiming Venture Partners（位于中国和相关的风险资本公司）的创业合伙人；1992年7月至2015年2月间担任Goldman Sachs（全球投资银行）的多项职位，包括全球医疗保健投资银行业务咨询主管（2010-2015），合伙人兼医疗保健投资研究联席主管（2002-2010），高级生物技术研究分析师（1992-2010）。在加入Goldman Sachs之前，她是Du Pont Merck Pharmaceutical Company的战略计划及许可主管。她目前也是Agios Pharmaceuticals的董事。
Maykin Ho has served as a member of Agios Pharmaceuticals, Inc. board of directors since June 2015. Dr. Ho has more than 30 years of experience in the healthcare and finance industries. She has been a venture partner at Qiming Venture Partners, a venture capital firm in China and Hong Kong, since July 2015. From July 1992 to February 2015 she held various positions at Goldman Sachs, a global investment bank, including: from 2010 to 2015 she served as advisory director of global healthcare investment banking; from 2002 to 2010 she served as partner and co-head of healthcare investment research; and from 1992 to 2010 she served as senior biotechnology research analyst. Prior to Goldman Sachs, Dr. Ho held various managerial positions in licensing, strategic planning, marketing and research at DuPont-Merck Pharmaceuticals, a global pharmaceutical company, and DuPont de Nemours & Company. She is a member of the board of directors and audit committee of Fibrogen, Inc., a publicly traded biotechnology company, a member of the board of directors and audit committee of Parexel International, a privately-held, global pharmaceutical services company, and a member of the board of directors, audit committee and science and technology committee of BioMarin Pharmaceutical Inc., a public biopharmaceutical company, and on the board of directors and audit committee of Neumora Therapeutics, Inc., a private biotechnology company. Dr. Ho previously served on the board of directors and audit committee as well as chaired the nominating and corporate governance committee of Grail, prior to its acquisition by Illumina. Dr. Ho also serves on the board of directors, audit committee and investment committee of two non-profit research institutes: the Aaron Diamond AIDS Research Center and the Institute for Protein Innovation. In addition, she is a member of the Biotech Advisory Panel of The Stock Exchange of Hong Kong. Previously, Dr. Ho served on the board of directors and audit committee of Parexel International when it was a publicly traded company, and on the investment committee of the Society of Neuroscience. She was a postdoctoral fellow at the pathology department of Harvard Medical School and a graduate of the Advanced Management Program at The Fuqua School of Business, Duke University. Dr. Ho received a Ph.D. in microbiology and immunology and a B.S. from the State University of New York, Downstate Medical Center. - Maykin Ho，2015年8月起担任董事，也是审计及财务委员会的成员。她自2015年7月起担任Qiming Venture Partners（位于中国和相关的风险资本公司）的创业合伙人；1992年7月至2015年2月间担任Goldman Sachs（全球投资银行）的多项职位，包括全球医疗保健投资银行业务咨询主管（2010-2015），合伙人兼医疗保健投资研究联席主管（2002-2010），高级生物技术研究分析师（1992-2010）。在加入Goldman Sachs之前，她是Du Pont Merck Pharmaceutical Company的战略计划及许可主管。她目前也是Agios Pharmaceuticals的董事。
- Maykin Ho has served as a member of Agios Pharmaceuticals, Inc. board of directors since June 2015. Dr. Ho has more than 30 years of experience in the healthcare and finance industries. She has been a venture partner at Qiming Venture Partners, a venture capital firm in China and Hong Kong, since July 2015. From July 1992 to February 2015 she held various positions at Goldman Sachs, a global investment bank, including: from 2010 to 2015 she served as advisory director of global healthcare investment banking; from 2002 to 2010 she served as partner and co-head of healthcare investment research; and from 1992 to 2010 she served as senior biotechnology research analyst. Prior to Goldman Sachs, Dr. Ho held various managerial positions in licensing, strategic planning, marketing and research at DuPont-Merck Pharmaceuticals, a global pharmaceutical company, and DuPont de Nemours & Company. She is a member of the board of directors and audit committee of Fibrogen, Inc., a publicly traded biotechnology company, a member of the board of directors and audit committee of Parexel International, a privately-held, global pharmaceutical services company, and a member of the board of directors, audit committee and science and technology committee of BioMarin Pharmaceutical Inc., a public biopharmaceutical company, and on the board of directors and audit committee of Neumora Therapeutics, Inc., a private biotechnology company. Dr. Ho previously served on the board of directors and audit committee as well as chaired the nominating and corporate governance committee of Grail, prior to its acquisition by Illumina. Dr. Ho also serves on the board of directors, audit committee and investment committee of two non-profit research institutes: the Aaron Diamond AIDS Research Center and the Institute for Protein Innovation. In addition, she is a member of the Biotech Advisory Panel of The Stock Exchange of Hong Kong. Previously, Dr. Ho served on the board of directors and audit committee of Parexel International when it was a publicly traded company, and on the investment committee of the Society of Neuroscience. She was a postdoctoral fellow at the pathology department of Harvard Medical School and a graduate of the Advanced Management Program at The Fuqua School of Business, Duke University. Dr. Ho received a Ph.D. in microbiology and immunology and a B.S. from the State University of New York, Downstate Medical Center.
- Willard Dere
-
Willard Dere，医学博士，自2016年10月起担任我们的董事之一。Dere博士担任内科教授；B.Lue和Hope S.Bettilyon担任糖尿病研究内科主席，个性化健康执行董事，犹他大学健康科学中心临床和转化科学中心的联合首席研究员。在2014年11月重新加入学术界之前，Dere博士在生物制药行业工作了25年。他于2003年加入Amgen公司，在那里他曾担任多种职务，包括全球开发、国际研究与开发主管，以及公司和国际首席医疗官。他曾领导Prolia公司的开发计划和其他几个计划，并于2014年10月退任Amgen公司。他的职业生涯始于1989年任职Eli Lilly公司，并在临床药理学、监管事务以及早期转化和后期临床研究中担任多种不同的全球职务。任职Eli Lilly公司期间，他曾领导Evista and Forteo公司的开发。Dere博士目前在RadiusHealth，Inc.董事会任职。纳斯达克市场代码:RDUS和Biomarin PharmaceuticalInc.（纳斯达克市场代码:BMRN），并担任加州再生医学研究所的科学顾问委员会成员。此前，Dere博士在犹他大学（University of Utah）的教员中任职四年，是美国医师学院（American College of Physicians）的研究员。Dere博士在加州大学戴维斯分校（University of California，Davis）获得工商管理硕士学位。
Willard Dere,is currently Professor Emeritus of Internal Medicine at the University of Utah and Chief Advisor to the Chief Executive Officer and Chief Medical Officer (part-time) at Angitia Biopharmaceuticals, a private biopharmaceutical company.Dr. Dere served as Professor of Internal Medicine and the B. Lue and Hope S. Bettilyon Presidential Endowed Chair in Internal Medicine for Diabetes Research, Co-Director of the Utah Clinical and Translational Science Institute, Co-Director of the Center for Genomic Medicine, and the Associate Vice President for Research at the University of Utah Health Sciences Center from November 2014 to June 2022. Prior to returning to academia in November 2014, Dr. Dere worked in the biopharmaceutical industry for 25 years, holding multiple roles at Amgen, Inc. and Eli Lilly and Company, both public biopharmaceutical companies.Dr. Dere currently serves on the boards of Mersana Therapeutics, Inc., Seres Therapeutics, Inc., and Metagenomi, Inc., all public biopharmaceutical companies. Dr. Dere served on the board of Ocera Therapeutics, Inc., a public biopharmaceutical company, until its acquisition by Mallinckrodt PLC in December 2017, and Radius Health, Inc., a public biopharmaceutical company, until its acquisition by a private equity firm in August 2022. Dr. Dere also serves on the external advisory board of the Utah Clinical and Translational Science Institute. Since 2014, Dr. Dere has served on the Grants Working Group of the California Institute of Regenerative Medicine.Dr. Dere holds a B.A. and an M.D. from the University of California, Davis, and trained in Internal Medicine at the University of Utah and Endocrinology/Metabolism at the University of California at San Francisco. - Willard Dere，医学博士，自2016年10月起担任我们的董事之一。Dere博士担任内科教授；B.Lue和Hope S.Bettilyon担任糖尿病研究内科主席，个性化健康执行董事，犹他大学健康科学中心临床和转化科学中心的联合首席研究员。在2014年11月重新加入学术界之前，Dere博士在生物制药行业工作了25年。他于2003年加入Amgen公司，在那里他曾担任多种职务，包括全球开发、国际研究与开发主管，以及公司和国际首席医疗官。他曾领导Prolia公司的开发计划和其他几个计划，并于2014年10月退任Amgen公司。他的职业生涯始于1989年任职Eli Lilly公司，并在临床药理学、监管事务以及早期转化和后期临床研究中担任多种不同的全球职务。任职Eli Lilly公司期间，他曾领导Evista and Forteo公司的开发。Dere博士目前在RadiusHealth，Inc.董事会任职。纳斯达克市场代码:RDUS和Biomarin PharmaceuticalInc.（纳斯达克市场代码:BMRN），并担任加州再生医学研究所的科学顾问委员会成员。此前，Dere博士在犹他大学（University of Utah）的教员中任职四年，是美国医师学院（American College of Physicians）的研究员。Dere博士在加州大学戴维斯分校（University of California，Davis）获得工商管理硕士学位。
- Willard Dere,is currently Professor Emeritus of Internal Medicine at the University of Utah and Chief Advisor to the Chief Executive Officer and Chief Medical Officer (part-time) at Angitia Biopharmaceuticals, a private biopharmaceutical company.Dr. Dere served as Professor of Internal Medicine and the B. Lue and Hope S. Bettilyon Presidential Endowed Chair in Internal Medicine for Diabetes Research, Co-Director of the Utah Clinical and Translational Science Institute, Co-Director of the Center for Genomic Medicine, and the Associate Vice President for Research at the University of Utah Health Sciences Center from November 2014 to June 2022. Prior to returning to academia in November 2014, Dr. Dere worked in the biopharmaceutical industry for 25 years, holding multiple roles at Amgen, Inc. and Eli Lilly and Company, both public biopharmaceutical companies.Dr. Dere currently serves on the boards of Mersana Therapeutics, Inc., Seres Therapeutics, Inc., and Metagenomi, Inc., all public biopharmaceutical companies. Dr. Dere served on the board of Ocera Therapeutics, Inc., a public biopharmaceutical company, until its acquisition by Mallinckrodt PLC in December 2017, and Radius Health, Inc., a public biopharmaceutical company, until its acquisition by a private equity firm in August 2022. Dr. Dere also serves on the external advisory board of the Utah Clinical and Translational Science Institute. Since 2014, Dr. Dere has served on the Grants Working Group of the California Institute of Regenerative Medicine.Dr. Dere holds a B.A. and an M.D. from the University of California, Davis, and trained in Internal Medicine at the University of Utah and Endocrinology/Metabolism at the University of California at San Francisco.
- Barbara W. Bodem
-
BarbaraW.Bodem高级副总裁和首席财务官当选，自2018年12月起生效。加入Hillrom公司之前，她曾担任Mallinckrodt公司的高级副总裁，财务。此前，她曾担任好比拉医疗保健公司和礼来公司（Eli Lilly）的多种高级财务职务，包括礼来肿瘤公司的首席财务官。
Barbara W. Bodem,was interim Chief Financial Officer of Dentsply Sirona Inc., a public dental equipment and supplies manufacturing company, from April 2022 to October 2022. Prior to that, she served as Senior Vice President and Chief Financial Officer of Hill-Rom Holdings, Inc., a medical device and medical technology provider, from 2018 until its acquisition by Baxter International Inc. in 2021. Earlier in her career, she served as Senior Vice President of Finance of Mallinckrodt Pharmaceuticals, a pharmaceutical manufacturer, from 2015 to 2018. She previously served in senior finance roles at Hospira, Inc. and Eli Lilly and Company.Ms. Bodem currently serves on the boards of Enovis Corp., a public medical technology company, and Option Care Health, Inc., a public provider of home and alternate site infusion services. She also serves on the boards of BiomEdit LLC, a private animal health company, NorthStar Medical Radioisotopes, a radiopharmaceutical company and the non-profit Nature Conservancy of Indiana. In the past five years, Ms. Bodem served on the boards of Syneos Health, Inc. and Turning Point Therapeutics, Inc. She also served on the board of Invacare Corporation.She holds a B.S. in Finance and an M.B.A from Indiana University. - BarbaraW.Bodem高级副总裁和首席财务官当选，自2018年12月起生效。加入Hillrom公司之前，她曾担任Mallinckrodt公司的高级副总裁，财务。此前，她曾担任好比拉医疗保健公司和礼来公司（Eli Lilly）的多种高级财务职务，包括礼来肿瘤公司的首席财务官。
- Barbara W. Bodem,was interim Chief Financial Officer of Dentsply Sirona Inc., a public dental equipment and supplies manufacturing company, from April 2022 to October 2022. Prior to that, she served as Senior Vice President and Chief Financial Officer of Hill-Rom Holdings, Inc., a medical device and medical technology provider, from 2018 until its acquisition by Baxter International Inc. in 2021. Earlier in her career, she served as Senior Vice President of Finance of Mallinckrodt Pharmaceuticals, a pharmaceutical manufacturer, from 2015 to 2018. She previously served in senior finance roles at Hospira, Inc. and Eli Lilly and Company.Ms. Bodem currently serves on the boards of Enovis Corp., a public medical technology company, and Option Care Health, Inc., a public provider of home and alternate site infusion services. She also serves on the boards of BiomEdit LLC, a private animal health company, NorthStar Medical Radioisotopes, a radiopharmaceutical company and the non-profit Nature Conservancy of Indiana. In the past five years, Ms. Bodem served on the boards of Syneos Health, Inc. and Turning Point Therapeutics, Inc. She also served on the board of Invacare Corporation.She holds a B.S. in Finance and an M.B.A from Indiana University.
- Elizabeth McKee Anderson
-
Elizabeth McKee Anderson自2015年3月以来一直担任我们的董事会成员。安德森女士自2019年7月起担任生物技术公司BioMarin Pharmaceutical的董事会成员。自2018年11月以来，安德森女士一直担任生物制药公司Insmed Incorporated的董事会成员。安德森女士自2017年4月起还担任生物技术公司Bavarian NordicA/S的董事会成员。安德森此前曾于2003年至2014年在Janssen Pharmaceuticals，Inc.担任多个职位，该公司是一家专注于制药的强生公司公司，最近的职位是2012年至2014年担任传染病和疫苗全球Vice President、商业领袖，以及全球Vice President、全球战略营销和市场准入，从2009年到2012年接种疫苗。在此之前，安德森女士曾担任惠氏Lederle Vaccines（一家制药公司）的Vice President和总经理。安德森女士获得了学士学位。持有Rutgers，the State University of New Jersey-New Brunswick的工程和技术管理学位，以及Loyola University of Maryland的金融工商管理硕士学位。
Elizabeth McKee Anderson has served as member of our board of directors since March 2015. Ms. Anderson has served as a member of the board of directors of BioMarin Pharmaceutical, a biotechnology company, since July 2019. Since November 2018 Ms. Anderson has served as a member of the board of directors of Insmed Incorporated, a biopharmaceutical company. Ms. Anderson has also served as a member of the board of directors of Bavarian Nordic A/S, a biotechnology company, since April 2017. Ms. Anderson previously served in various roles at Janssen Pharmaceuticals, Inc., a Johnson & Johnson company focusing on pharmaceuticals, from 2003 to 2014 most recently as Worldwide Vice President, Commercial Leader, Infectious Diseases and Vaccines, from 2012 to 2014 and Worldwide Vice President, Global Strategic Marketing and Market Access, Vaccines from 2009 to 2012. Prior to that, Ms. Anderson served as Vice President and General Manager for Wyeth Lederle Vaccines, a pharmaceutical company. Ms. Anderson received a B.Eng. in Engineering and Technical Management from Rutgers, The State University of New Jersey-New Brunswick and an M.B.A. in Finance from Loyola University of Maryland. - Elizabeth McKee Anderson自2015年3月以来一直担任我们的董事会成员。安德森女士自2019年7月起担任生物技术公司BioMarin Pharmaceutical的董事会成员。自2018年11月以来，安德森女士一直担任生物制药公司Insmed Incorporated的董事会成员。安德森女士自2017年4月起还担任生物技术公司Bavarian NordicA/S的董事会成员。安德森此前曾于2003年至2014年在Janssen Pharmaceuticals，Inc.担任多个职位，该公司是一家专注于制药的强生公司公司，最近的职位是2012年至2014年担任传染病和疫苗全球Vice President、商业领袖，以及全球Vice President、全球战略营销和市场准入，从2009年到2012年接种疫苗。在此之前，安德森女士曾担任惠氏Lederle Vaccines（一家制药公司）的Vice President和总经理。安德森女士获得了学士学位。持有Rutgers，the State University of New Jersey-New Brunswick的工程和技术管理学位，以及Loyola University of Maryland的金融工商管理硕士学位。
- Elizabeth McKee Anderson has served as member of our board of directors since March 2015. Ms. Anderson has served as a member of the board of directors of BioMarin Pharmaceutical, a biotechnology company, since July 2019. Since November 2018 Ms. Anderson has served as a member of the board of directors of Insmed Incorporated, a biopharmaceutical company. Ms. Anderson has also served as a member of the board of directors of Bavarian Nordic A/S, a biotechnology company, since April 2017. Ms. Anderson previously served in various roles at Janssen Pharmaceuticals, Inc., a Johnson & Johnson company focusing on pharmaceuticals, from 2003 to 2014 most recently as Worldwide Vice President, Commercial Leader, Infectious Diseases and Vaccines, from 2012 to 2014 and Worldwide Vice President, Global Strategic Marketing and Market Access, Vaccines from 2009 to 2012. Prior to that, Ms. Anderson served as Vice President and General Manager for Wyeth Lederle Vaccines, a pharmaceutical company. Ms. Anderson received a B.Eng. in Engineering and Technical Management from Rutgers, The State University of New Jersey-New Brunswick and an M.B.A. in Finance from Loyola University of Maryland.
- Alexander Hardy
-
Alexander Hardy，曾在Genentech，Inc.和罗氏（Roche）工作近20年，最近自2019年5月起担任Genentech，Inc.首席执行官。在罗氏，Hardy先生曾于2016年8月至2019年3月担任全球产品战略主管，并于2014年5月至2016年8月担任罗氏制药亚太区主管。在此之前，Hardy先生曾在基因泰克（在被罗氏收购之前）和诺华担任过各种领导职务。他目前担任美国药物研究和制造商（PhRMA）的董事会成员。哈迪先生拥有剑桥大学土地经济学士学位和密歇根大学罗斯商学院工商管理硕士学位。
Alexander Hardy,spent nearly 20 years at Genentech, Inc. and Roche, most recently serving as Chief Executive Officer of Genentech, Inc. since May 2019. At Roche, Mr. Hardy previously served as Head of Global Product Strategy from August 2016 to March 2019, and as Head, Asia Pacific, Roche Pharma, from May 2014 through August 2016. Before that, Mr. Hardy served in various leadership roles at Genentech, Inc. (prior to its acquisition by Roche) and Novartis. He currently serves on the board of directors for the Pharmaceutical Research and Manufacturers of America (PhRMA).Mr. Hardy holds a B.A. in Land Economy from the University of Cambridge and an M.B.A. from the University of Michigan's Ross School of Business. - Alexander Hardy，曾在Genentech，Inc.和罗氏（Roche）工作近20年，最近自2019年5月起担任Genentech，Inc.首席执行官。在罗氏，Hardy先生曾于2016年8月至2019年3月担任全球产品战略主管，并于2014年5月至2016年8月担任罗氏制药亚太区主管。在此之前，Hardy先生曾在基因泰克（在被罗氏收购之前）和诺华担任过各种领导职务。他目前担任美国药物研究和制造商（PhRMA）的董事会成员。哈迪先生拥有剑桥大学土地经济学士学位和密歇根大学罗斯商学院工商管理硕士学位。
- Alexander Hardy,spent nearly 20 years at Genentech, Inc. and Roche, most recently serving as Chief Executive Officer of Genentech, Inc. since May 2019. At Roche, Mr. Hardy previously served as Head of Global Product Strategy from August 2016 to March 2019, and as Head, Asia Pacific, Roche Pharma, from May 2014 through August 2016. Before that, Mr. Hardy served in various leadership roles at Genentech, Inc. (prior to its acquisition by Roche) and Novartis. He currently serves on the board of directors for the Pharmaceutical Research and Manufacturers of America (PhRMA).Mr. Hardy holds a B.A. in Land Economy from the University of Cambridge and an M.B.A. from the University of Michigan's Ross School of Business.
- Ian T. Clark
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Robert J. Hombach
-
Robert J. Hombach，曾担任上市生物制药公司Baxalta Inc.的执行副总裁、首席财务官和首席运营官，直至2016年6月被Shire plc收购。Baxalta于2015年7月从母公司百特国际 Inc.分拆出来，Hombach先生曾担任公司副总裁兼首席财务官。Hombach先生目前在上市生物技术公司BioMarin Pharmaceuticals Inc.和上市糖尿病公司Embecta Corporation的董事会任职。他此前还曾在Aptinyx Inc.、CarMax，Inc.、Naurex，Inc.和Surgical Innovation Associates，Inc.的董事会任职。Hombach先生拥有西北大学J.L。 家乐氏管理研究生院的工商管理硕士学位和科罗拉多大学的以优异成绩获得的金融学士学位。
Robert J. Hombach served as Executive Vice President, Chief Financial Officer and Chief Operations Officer of Baxalta Incorporated until 2016, a biopharmaceutical company spun out from Baxter International, Inc. ("Baxter") (NYSE: BAX). He served as Corporate Vice President and Chief Financial Officer of Baxter from July 2010 until the spinoff in 2015. From 2007 to 2011, Mr. Hombach served as Treasurer of Baxter and from 2004 to 2007, he was Vice President of Finance, Europe, Middle East and Africa at Baxter. Prior to that, Mr. Hombach served in a number of finance positions of increasing responsibility in the corporate planning, manufacturing, operations and treasury areas at Baxter. Mr. Hombach is currently a member of the Board of Directors of BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) and Henry Schein, Inc. (NASDAQ: HSIC). - Robert J. Hombach，曾担任上市生物制药公司Baxalta Inc.的执行副总裁、首席财务官和首席运营官，直至2016年6月被Shire plc收购。Baxalta于2015年7月从母公司百特国际 Inc.分拆出来，Hombach先生曾担任公司副总裁兼首席财务官。Hombach先生目前在上市生物技术公司BioMarin Pharmaceuticals Inc.和上市糖尿病公司Embecta Corporation的董事会任职。他此前还曾在Aptinyx Inc.、CarMax，Inc.、Naurex，Inc.和Surgical Innovation Associates，Inc.的董事会任职。Hombach先生拥有西北大学J.L。 家乐氏管理研究生院的工商管理硕士学位和科罗拉多大学的以优异成绩获得的金融学士学位。
- Robert J. Hombach served as Executive Vice President, Chief Financial Officer and Chief Operations Officer of Baxalta Incorporated until 2016, a biopharmaceutical company spun out from Baxter International, Inc. ("Baxter") (NYSE: BAX). He served as Corporate Vice President and Chief Financial Officer of Baxter from July 2010 until the spinoff in 2015. From 2007 to 2011, Mr. Hombach served as Treasurer of Baxter and from 2004 to 2007, he was Vice President of Finance, Europe, Middle East and Africa at Baxter. Prior to that, Mr. Hombach served in a number of finance positions of increasing responsibility in the corporate planning, manufacturing, operations and treasury areas at Baxter. Mr. Hombach is currently a member of the Board of Directors of BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) and Henry Schein, Inc. (NASDAQ: HSIC).
- Richard A. Meier
-
Richard A. Meier自2013年3月起开始担任 Owens & Minor公司（一家执行医疗保健服务的全球供应商）副总裁和首席财务官。自2006年起担任BioMarin制药有限公司董事；2010年3月开始担任审计完委员会主席。从2010年1月到2012年3月担任Teleflex（一家医疗设备的全球供应商）执行副总裁和首席财务官。之前他曾于2007年2月担任Advanced Medical Optics公司总裁和首席运营官，直到2009年4月公司被雅培公司 收购。AMO是眼科手术界最大的公司之一。从2006年4月到2007年2月他担任AMO运营部执行副总裁；全球眼部护理总裁和首席财务官。从2004年2月到2006年4月他担任AMO运营部和金融部执行副总裁和首席财务官。从2002年4月到2004年2月担任公司副总裁和首席财务官。加入AMO之前，他从1999年10月开始担任Valeant制药公司执行副总裁和首席财务官；从1998年到1999年10月担任高级副总裁和风险官。加入Valeant之前，他在纽约一家投资银行-- Schroder 公司担任执行官。加入 Schroder 公司之前，他在所罗门美邦公司、汉诺威制造公司、澳大利亚资本公司以及Greyhound Lines公司担任多个金融和银行职位。他是普林斯顿大学毕业生，持有经济学学士学位。
Richard A. Meier joined Biomarin Pharmaceutical Inc.'s Board in December 2006 and serves as the Chair of the Audit Committee and has served as Biomarin Pharmaceutical Inc. Lead Independent Director since June 2015. In March of 2013 Mr. Meier joined Owens & Minor, Inc., a global healthcare services company, as Executive Vice President and Chief Financial Officer, and was promoted to President-International and Executive Vice President and Chief Financial Officer, as of July 2015. From January 2010 through March 2012 Mr. Meier was an Executive Vice President and Chief Financial Officer at TeleFlex, Incorporated, a global medical device company. From November 2007 to May 2009 Mr. Meier served as President and Chief Operating Officer of Advanced Medical Optics, a global ophthalmic medical device company that was acquired by Abbott in February 2009. Between April 2002 and November 2007 Mr. Meier served continuously as Advanced Medical Optics'Chief Financial Officer, while serving in a variety of additional senior operating roles. Prior to joining Advanced Medical Optics, Mr. Meier was the Executive Vice President and Chief Financial Officer of Valeant Pharmaceuticals, Inc. formerly ICN Pharmaceuticals, Inc., from October 1999 to April 2002 and Senior Vice President & Treasurer from May 1998 to October 1999. Before joining ICN Pharmaceuticals, Inc., Mr. Meier was an executive with the investment banking firm of Schroder & Co. Inc. in New York, from 1996. Prior to Mr. Meier's experience at Schroder & Co., he held various financial and banking positions at Salomon Smith Barney, Manufacturers Hanover Corporation, Australian Capital Equity, and Greyhound Lines, Inc. Mr. Meier was a Director of Staar Surgical Inc., an ophthalmic medical device company, from 2009 through June 2016 where he also served on both the Governance and Audit Committees. Mr. Meier holds a B.A. in economics from Princeton University. - Richard A. Meier自2013年3月起开始担任 Owens & Minor公司（一家执行医疗保健服务的全球供应商）副总裁和首席财务官。自2006年起担任BioMarin制药有限公司董事；2010年3月开始担任审计完委员会主席。从2010年1月到2012年3月担任Teleflex（一家医疗设备的全球供应商）执行副总裁和首席财务官。之前他曾于2007年2月担任Advanced Medical Optics公司总裁和首席运营官，直到2009年4月公司被雅培公司 收购。AMO是眼科手术界最大的公司之一。从2006年4月到2007年2月他担任AMO运营部执行副总裁；全球眼部护理总裁和首席财务官。从2004年2月到2006年4月他担任AMO运营部和金融部执行副总裁和首席财务官。从2002年4月到2004年2月担任公司副总裁和首席财务官。加入AMO之前，他从1999年10月开始担任Valeant制药公司执行副总裁和首席财务官；从1998年到1999年10月担任高级副总裁和风险官。加入Valeant之前，他在纽约一家投资银行-- Schroder 公司担任执行官。加入 Schroder 公司之前，他在所罗门美邦公司、汉诺威制造公司、澳大利亚资本公司以及Greyhound Lines公司担任多个金融和银行职位。他是普林斯顿大学毕业生，持有经济学学士学位。
- Richard A. Meier joined Biomarin Pharmaceutical Inc.'s Board in December 2006 and serves as the Chair of the Audit Committee and has served as Biomarin Pharmaceutical Inc. Lead Independent Director since June 2015. In March of 2013 Mr. Meier joined Owens & Minor, Inc., a global healthcare services company, as Executive Vice President and Chief Financial Officer, and was promoted to President-International and Executive Vice President and Chief Financial Officer, as of July 2015. From January 2010 through March 2012 Mr. Meier was an Executive Vice President and Chief Financial Officer at TeleFlex, Incorporated, a global medical device company. From November 2007 to May 2009 Mr. Meier served as President and Chief Operating Officer of Advanced Medical Optics, a global ophthalmic medical device company that was acquired by Abbott in February 2009. Between April 2002 and November 2007 Mr. Meier served continuously as Advanced Medical Optics'Chief Financial Officer, while serving in a variety of additional senior operating roles. Prior to joining Advanced Medical Optics, Mr. Meier was the Executive Vice President and Chief Financial Officer of Valeant Pharmaceuticals, Inc. formerly ICN Pharmaceuticals, Inc., from October 1999 to April 2002 and Senior Vice President & Treasurer from May 1998 to October 1999. Before joining ICN Pharmaceuticals, Inc., Mr. Meier was an executive with the investment banking firm of Schroder & Co. Inc. in New York, from 1996. Prior to Mr. Meier's experience at Schroder & Co., he held various financial and banking positions at Salomon Smith Barney, Manufacturers Hanover Corporation, Australian Capital Equity, and Greyhound Lines, Inc. Mr. Meier was a Director of Staar Surgical Inc., an ophthalmic medical device company, from 2009 through June 2016 where he also served on both the Governance and Audit Committees. Mr. Meier holds a B.A. in economics from Princeton University.
- Timothy P. Walbert
-
Timothy P. Walbert，自2010年公司成立起任公司的董事会主席，总裁兼首席执行官。他自2008年6月起也是Horizon Pharma USA的总裁兼首席执行官。2007年5月至2009年6月，他是IDM Pharma, Inc.的总裁、董事兼首席执行官；公司是一家生物制药公司，于2009 年6月被Takeda America Holdings, Inc. 收购。2006年1月至2007年5月，他是NeoPharm, Inc.的商业运营执行副总裁。2001年6月至2005年8月，他是Immunology的区域副总裁兼总经理，在此他领导HUMIRA的全球发展——于2013年超过110亿美元；且是Abbott全球心血管战略执行副总裁，该组织是一家医疗保健公司，现为AbbVie。1998年4月至2001年6月，他是Celebrex North America的董事，以及G.D. Searle & Company 亚太区、拉丁美洲及加拿大的关节炎团队负责人。1991年至1998年，他在G.D. Searle, Merck & Co., Inc.和 Wyeth。担任销售和营销职务。 他持有Muhlenberg College理学士学位。他也在 XOMA Corporation （纳斯达克： XOMA） 、Raptor Pharmaceutical Corp. （纳斯达克： RPTP）、Egalet Corporation （纳斯达克： EGLT）、生物技术工业组织 （BIO）、伊利诺斯州生物技术工业组织 （iBIO）、 ChicagoNEXT、 a World Business Chicago （WBC） led council of technology leaders ，以及芝加哥关节炎基金会（the Greater Chicago Arthritis Foundation）的董事会任职。2013年，他被任命为 伊利诺斯州创新委员会（the Illinois Innovation Council）的主管人员。
Timothy P. Walbert,has served as Horizon Therapeutics Public Limited Company president, chief executive officer and director of Horizon since June 2008 and has served as Horizon Therapeutics Public Limited Company chairman since March 2010. From May 2007 to June 2009, Mr. Walbert served as president, chief executive officer and director of IDM Pharma, Inc., a public biotechnology company that was acquired by Takeda America Holdings, Inc. in June 2009. Prior to that, he served as executive vice president, commercial operations of NeoPharm, Inc., a public biotechnology company. From June 2001 to August 2005, Mr. Walbert served as divisional vice president and general manager of immunology, where he built and led the global development and launch of the multi-indication biologic HUMIRA, and divisional vice president, global cardiovascular strategy at Abbott, now AbbVie. From 1998 to 2001, he served as director, CELEBREX North America and arthritis team leader, Asia Pacific, Latin America and Canada at G.D. Searle & Company. Mr. Walbert has served on the boards of directors of Century Therapeutics, Inc., a public biotechnology company, since October 2022, Mirum Pharmaceuticals, Inc., a public biotechnology company, since April 2023, and he sits on the board of directors of the Illinois Biotechnology Innovation Organization (iBIO). Mr. Walbert is also a member of the National Organization for Rare Disorders (NORD) Advisory Board and serves on the Board of Trustees of Muhlenberg College. He previously served as chairman of the board of directors of Exicure, Inc., a public clinical-stage biotechnology company, from July 2019 to February 2022, and on the boards of directors of Aurinia Pharmaceuticals, Inc. a public biotechnology company, from April 2020 to September 2022; Assertio Holdings, Inc., a public specialty pharmaceutical company, from May 2020 to December 2020 (and before that at Zyla Life Sciences, a public pharmaceutical company, from April 2014 until May 2020, when it was acquired by Assertio); and Sucampo Pharmaceuticals, Inc., a public biopharma company, from 2016 to 2018, when it was acquired by Mallinckrodt. Mr. Walbert received his bachelor of arts degree in business from Muhlenberg College, in Allentown, Pennsylvania. - Timothy P. Walbert，自2010年公司成立起任公司的董事会主席，总裁兼首席执行官。他自2008年6月起也是Horizon Pharma USA的总裁兼首席执行官。2007年5月至2009年6月，他是IDM Pharma, Inc.的总裁、董事兼首席执行官；公司是一家生物制药公司，于2009 年6月被Takeda America Holdings, Inc. 收购。2006年1月至2007年5月，他是NeoPharm, Inc.的商业运营执行副总裁。2001年6月至2005年8月，他是Immunology的区域副总裁兼总经理，在此他领导HUMIRA的全球发展——于2013年超过110亿美元；且是Abbott全球心血管战略执行副总裁，该组织是一家医疗保健公司，现为AbbVie。1998年4月至2001年6月，他是Celebrex North America的董事，以及G.D. Searle & Company 亚太区、拉丁美洲及加拿大的关节炎团队负责人。1991年至1998年，他在G.D. Searle, Merck & Co., Inc.和 Wyeth。担任销售和营销职务。 他持有Muhlenberg College理学士学位。他也在 XOMA Corporation （纳斯达克： XOMA） 、Raptor Pharmaceutical Corp. （纳斯达克： RPTP）、Egalet Corporation （纳斯达克： EGLT）、生物技术工业组织 （BIO）、伊利诺斯州生物技术工业组织 （iBIO）、 ChicagoNEXT、 a World Business Chicago （WBC） led council of technology leaders ，以及芝加哥关节炎基金会（the Greater Chicago Arthritis Foundation）的董事会任职。2013年，他被任命为 伊利诺斯州创新委员会（the Illinois Innovation Council）的主管人员。
- Timothy P. Walbert,has served as Horizon Therapeutics Public Limited Company president, chief executive officer and director of Horizon since June 2008 and has served as Horizon Therapeutics Public Limited Company chairman since March 2010. From May 2007 to June 2009, Mr. Walbert served as president, chief executive officer and director of IDM Pharma, Inc., a public biotechnology company that was acquired by Takeda America Holdings, Inc. in June 2009. Prior to that, he served as executive vice president, commercial operations of NeoPharm, Inc., a public biotechnology company. From June 2001 to August 2005, Mr. Walbert served as divisional vice president and general manager of immunology, where he built and led the global development and launch of the multi-indication biologic HUMIRA, and divisional vice president, global cardiovascular strategy at Abbott, now AbbVie. From 1998 to 2001, he served as director, CELEBREX North America and arthritis team leader, Asia Pacific, Latin America and Canada at G.D. Searle & Company. Mr. Walbert has served on the boards of directors of Century Therapeutics, Inc., a public biotechnology company, since October 2022, Mirum Pharmaceuticals, Inc., a public biotechnology company, since April 2023, and he sits on the board of directors of the Illinois Biotechnology Innovation Organization (iBIO). Mr. Walbert is also a member of the National Organization for Rare Disorders (NORD) Advisory Board and serves on the Board of Trustees of Muhlenberg College. He previously served as chairman of the board of directors of Exicure, Inc., a public clinical-stage biotechnology company, from July 2019 to February 2022, and on the boards of directors of Aurinia Pharmaceuticals, Inc. a public biotechnology company, from April 2020 to September 2022; Assertio Holdings, Inc., a public specialty pharmaceutical company, from May 2020 to December 2020 (and before that at Zyla Life Sciences, a public pharmaceutical company, from April 2014 until May 2020, when it was acquired by Assertio); and Sucampo Pharmaceuticals, Inc., a public biopharma company, from 2016 to 2018, when it was acquired by Mallinckrodt. Mr. Walbert received his bachelor of arts degree in business from Muhlenberg College, in Allentown, Pennsylvania.
- Athena Countouriotis
-
Athena Countouriotis自2018年10月起担任Turning Point医疗公司的首席执行官和董事会成员，并于2018年5月至2018年9月期间担任Turning Point医疗的首席医疗官。Countouriotis博士于2017年6月至2018年5月担任Adverum生物科技公司高级副总裁兼首席医疗官，在此之前于2015年1月至2017年5月担任奥洛兹美医疗公司高级副总裁兼首席医疗官。Countouriotis博士还从2012年2月起担任Ambit Biosciences Corporation的首席医疗官，直到2014年11月Ambit被Daiichi Sankyo公司收购。在她职业生涯的早期，Countouriotis博士曾领导辉瑞公司和百时美施贵宝公司内的多个肿瘤治疗临床开发组织。Countouriotis博士目前在Iovance Biotherapeutics，Inc.和Trovagene，Inc.的董事会任职，这两家公司都是上市的肿瘤治疗公司。Countouriotis博士获得了加州大学洛杉矶分校的学士学位和塔夫茨大学医学院的医学博士学位。她在加州大学洛杉矶分校接受了最初的儿科培训，并在Fred Hutchinson癌症研究中心接受了儿科血液学/肿瘤学项目的额外培训。
Athena Countouriotis has served as Chief Executive Officer and a member of the board of directors of Turning Point Therapeutics Inc. since October 2018 and from May 2018 to September 2018 she served as Chief Medical Officer of Turning Point Therapeutics. Dr. Countouriotis served as Senior Vice President and Chief Medical Officer for Adverum Biotechnologies, Inc. from June 2017 to May 2018 and before that served as Senior Vice President, Chief Medical Officer of Halozyme Therapeutics, Inc. from January 2015 to May 2017. Dr. Countouriotis also served as Chief Medical Officer of Ambit Biosciences Corporation from February 2012 until Ambit's acquisition by Daiichi Sankyo Company in November 2014. Earlier in her career, Dr. Countouriotis led various clinical development organizations within Pfizer Inc. and Bristol-Myers Squibb Company for oncology therapeutics. Dr. Countouriotis currently serves on the boards of directors of Iovance Biotherapeutics, Inc. and Trovagene, Inc., both public oncology therapeutics companies. Dr. Countouriotis earned a B.S. from the University of California, Los Angeles, and an M.D. from Tufts University School of Medicine. She received her initial training in pediatrics at the University of California, Los Angeles, and additional training at the Fred Hutchinson Cancer Research Center in the Pediatric Hematology/Oncology Program. - Athena Countouriotis自2018年10月起担任Turning Point医疗公司的首席执行官和董事会成员，并于2018年5月至2018年9月期间担任Turning Point医疗的首席医疗官。Countouriotis博士于2017年6月至2018年5月担任Adverum生物科技公司高级副总裁兼首席医疗官，在此之前于2015年1月至2017年5月担任奥洛兹美医疗公司高级副总裁兼首席医疗官。Countouriotis博士还从2012年2月起担任Ambit Biosciences Corporation的首席医疗官，直到2014年11月Ambit被Daiichi Sankyo公司收购。在她职业生涯的早期，Countouriotis博士曾领导辉瑞公司和百时美施贵宝公司内的多个肿瘤治疗临床开发组织。Countouriotis博士目前在Iovance Biotherapeutics，Inc.和Trovagene，Inc.的董事会任职，这两家公司都是上市的肿瘤治疗公司。Countouriotis博士获得了加州大学洛杉矶分校的学士学位和塔夫茨大学医学院的医学博士学位。她在加州大学洛杉矶分校接受了最初的儿科培训，并在Fred Hutchinson癌症研究中心接受了儿科血液学/肿瘤学项目的额外培训。
- Athena Countouriotis has served as Chief Executive Officer and a member of the board of directors of Turning Point Therapeutics Inc. since October 2018 and from May 2018 to September 2018 she served as Chief Medical Officer of Turning Point Therapeutics. Dr. Countouriotis served as Senior Vice President and Chief Medical Officer for Adverum Biotechnologies, Inc. from June 2017 to May 2018 and before that served as Senior Vice President, Chief Medical Officer of Halozyme Therapeutics, Inc. from January 2015 to May 2017. Dr. Countouriotis also served as Chief Medical Officer of Ambit Biosciences Corporation from February 2012 until Ambit's acquisition by Daiichi Sankyo Company in November 2014. Earlier in her career, Dr. Countouriotis led various clinical development organizations within Pfizer Inc. and Bristol-Myers Squibb Company for oncology therapeutics. Dr. Countouriotis currently serves on the boards of directors of Iovance Biotherapeutics, Inc. and Trovagene, Inc., both public oncology therapeutics companies. Dr. Countouriotis earned a B.S. from the University of California, Los Angeles, and an M.D. from Tufts University School of Medicine. She received her initial training in pediatrics at the University of California, Los Angeles, and additional training at the Fred Hutchinson Cancer Research Center in the Pediatric Hematology/Oncology Program.
- Mark J. Enyedy
-
Mark J. Enyedy， 曾于2016年5月至2024年2月担任上市生物技术公司ImmunoGen, Inc.的总裁兼首席执行官，当时TERM1，Inc.被艾伯维公司收购。Enyedy从制药公司Shire plc加入ImmunoGen，曾于2013年8月至2016年5月担任各种执行职务，包括2014年5月至2016年5月担任执行副总裁兼企业发展主管。在此之前，他于2011年9月至2013年8月担任生物制药公司Proteostasis Therapeutics, Inc.的首席执行官兼董事。在加入Proteostasis之前，他曾在生物制药公司健赞服务了15年。Enyedy先生在加入健赞之前是波士顿Palmer & Dodge律师事务所的合伙人。Enyedy目前担任Ergomed PLC的私人控股公司Eden Topco Limited的董事。过去五年内，他曾担任Ergomed PLC、LogicBio医疗，Inc.、Akebia Therapeutics, Inc. Enyedy先生的董事。他还曾在Fate Therapeutics, Inc.、Keryx Biopharmaceuticals, Inc.、新英格兰东部美国癌症协会、生物技术创新组织的董事会任职。他拥有东北大学的学士学位和哈佛大学法学院的法学博士学位。
Mark J. Enyedy,served as the President and Chief Executive Officer of ImmunoGen, Inc., a public biotechnology company, from May 2016 until February 2024, when ImmunoGen, Inc. was acquired by AbbVie Inc.Mr. Enyedy joined ImmunoGen from Shire plc, a pharmaceutical company, where he served in various executive capacities from August 2013 to May 2016, including as Executive Vice President and Head of Corporate Development from May 2014 to May 2016. Prior to that, he served as Chief Executive Officer and a director of Proteostasis Therapeutics, Inc., a biopharmaceutical company, from September 2011 to August 2013. Prior to joining Proteostasis, he served for 15 years at Genzyme Corporation, a biopharmaceutical company. Before joining Genzyme Corporation, Mr. Enyedy was an Associate with the Boston law firm Palmer & Dodge.Mr. Enyedy currently serves as a director of Eden Topco Limited, a private holding company for Ergomed plc. Within the past five years, he served as a director of Ergomed plc, LogicBio Therapeutics, Inc., and Akebia Therapeutics, Inc. Mr. Enyedy also served on the boards of Fate Therapeutics, Inc., Keryx Biopharmaceuticals, Inc., the American Cancer Society of Eastern New England, and The Biotechnology Innovation Organization.He holds a B.S. from Northeastern University and a J.D. from Harvard Law School. - Mark J. Enyedy， 曾于2016年5月至2024年2月担任上市生物技术公司ImmunoGen, Inc.的总裁兼首席执行官，当时TERM1，Inc.被艾伯维公司收购。Enyedy从制药公司Shire plc加入ImmunoGen，曾于2013年8月至2016年5月担任各种执行职务，包括2014年5月至2016年5月担任执行副总裁兼企业发展主管。在此之前，他于2011年9月至2013年8月担任生物制药公司Proteostasis Therapeutics, Inc.的首席执行官兼董事。在加入Proteostasis之前，他曾在生物制药公司健赞服务了15年。Enyedy先生在加入健赞之前是波士顿Palmer & Dodge律师事务所的合伙人。Enyedy目前担任Ergomed PLC的私人控股公司Eden Topco Limited的董事。过去五年内，他曾担任Ergomed PLC、LogicBio医疗，Inc.、Akebia Therapeutics, Inc. Enyedy先生的董事。他还曾在Fate Therapeutics, Inc.、Keryx Biopharmaceuticals, Inc.、新英格兰东部美国癌症协会、生物技术创新组织的董事会任职。他拥有东北大学的学士学位和哈佛大学法学院的法学博士学位。
- Mark J. Enyedy,served as the President and Chief Executive Officer of ImmunoGen, Inc., a public biotechnology company, from May 2016 until February 2024, when ImmunoGen, Inc. was acquired by AbbVie Inc.Mr. Enyedy joined ImmunoGen from Shire plc, a pharmaceutical company, where he served in various executive capacities from August 2013 to May 2016, including as Executive Vice President and Head of Corporate Development from May 2014 to May 2016. Prior to that, he served as Chief Executive Officer and a director of Proteostasis Therapeutics, Inc., a biopharmaceutical company, from September 2011 to August 2013. Prior to joining Proteostasis, he served for 15 years at Genzyme Corporation, a biopharmaceutical company. Before joining Genzyme Corporation, Mr. Enyedy was an Associate with the Boston law firm Palmer & Dodge.Mr. Enyedy currently serves as a director of Eden Topco Limited, a private holding company for Ergomed plc. Within the past five years, he served as a director of Ergomed plc, LogicBio Therapeutics, Inc., and Akebia Therapeutics, Inc. Mr. Enyedy also served on the boards of Fate Therapeutics, Inc., Keryx Biopharmaceuticals, Inc., the American Cancer Society of Eastern New England, and The Biotechnology Innovation Organization.He holds a B.S. from Northeastern University and a J.D. from Harvard Law School.
高管简历
中英对照 | 中文 | 英文- Alexander Hardy
Alexander Hardy，曾在Genentech，Inc.和罗氏（Roche）工作近20年，最近自2019年5月起担任Genentech，Inc.首席执行官。在罗氏，Hardy先生曾于2016年8月至2019年3月担任全球产品战略主管，并于2014年5月至2016年8月担任罗氏制药亚太区主管。在此之前，Hardy先生曾在基因泰克（在被罗氏收购之前）和诺华担任过各种领导职务。他目前担任美国药物研究和制造商（PhRMA）的董事会成员。哈迪先生拥有剑桥大学土地经济学士学位和密歇根大学罗斯商学院工商管理硕士学位。
Alexander Hardy,spent nearly 20 years at Genentech, Inc. and Roche, most recently serving as Chief Executive Officer of Genentech, Inc. since May 2019. At Roche, Mr. Hardy previously served as Head of Global Product Strategy from August 2016 to March 2019, and as Head, Asia Pacific, Roche Pharma, from May 2014 through August 2016. Before that, Mr. Hardy served in various leadership roles at Genentech, Inc. (prior to its acquisition by Roche) and Novartis. He currently serves on the board of directors for the Pharmaceutical Research and Manufacturers of America (PhRMA).Mr. Hardy holds a B.A. in Land Economy from the University of Cambridge and an M.B.A. from the University of Michigan's Ross School of Business.- Alexander Hardy，曾在Genentech，Inc.和罗氏（Roche）工作近20年，最近自2019年5月起担任Genentech，Inc.首席执行官。在罗氏，Hardy先生曾于2016年8月至2019年3月担任全球产品战略主管，并于2014年5月至2016年8月担任罗氏制药亚太区主管。在此之前，Hardy先生曾在基因泰克（在被罗氏收购之前）和诺华担任过各种领导职务。他目前担任美国药物研究和制造商（PhRMA）的董事会成员。哈迪先生拥有剑桥大学土地经济学士学位和密歇根大学罗斯商学院工商管理硕士学位。
- Alexander Hardy,spent nearly 20 years at Genentech, Inc. and Roche, most recently serving as Chief Executive Officer of Genentech, Inc. since May 2019. At Roche, Mr. Hardy previously served as Head of Global Product Strategy from August 2016 to March 2019, and as Head, Asia Pacific, Roche Pharma, from May 2014 through August 2016. Before that, Mr. Hardy served in various leadership roles at Genentech, Inc. (prior to its acquisition by Roche) and Novartis. He currently serves on the board of directors for the Pharmaceutical Research and Manufacturers of America (PhRMA).Mr. Hardy holds a B.A. in Land Economy from the University of Cambridge and an M.B.A. from the University of Michigan's Ross School of Business.
- Gregory R. Friberg
Gregory R. Friberg，2024年9月加入BioMarin，现任执行副总裁兼首席研发官。Friberg博士负责BioMarin的发现研究、临床前、转化和临床项目，以及全球监管和医疗事务。在加入BioMarin之前，Friberg博士在生物技术公司安进工作了18年，最近担任该公司罕见病全球医疗事务副总裁。在任职安进期间，他负责推进从研究性新药申请备案到后期开发的多种药物，还担任安进血液学/肿瘤学和骨骼产品组合的全球开发主管。在开始生物制药行业的职业生涯之前，弗里伯格博士曾在芝加哥大学任教。现任美国临床肿瘤学会、美国癌症研究协会会员。弗里伯格博士拥有米德尔伯里学院的生物化学A.B.和纽约医学院的医学博士学位。他在达特茅斯-希区柯克医学中心完成了内科住院医师实习，并在芝加哥大学医学中心完成了血液学和肿瘤学研究金。
Gregory R. Friberg,joined BioMarin in September 2024 and currently serves as Executive Vice President and Chief Research & Development Officer. Dr. Friberg is responsible for BioMarin's discovery research, preclinical, translational and clinical programs, as well as global regulatory and medical affairs. Prior to joining BioMarin, Dr. Friberg spent 18 years at Amgen, a biotechnology company, where he served most recently as Vice President, Global Medical Affairs, Rare Disease. During his time at Amgen, he was responsible for advancing multiple medicines from investigational new drug application filing through late-stage development, and also served as the head of global development for Amgen's hematology/oncology and bone portfolios. Before beginning his career in the biopharma industry, Dr. Friberg served on the faculty of the University of Chicago. He is currently a member of the American Society of Clinical Oncology and the American Association for Cancer Research. Dr. Friberg holds an A.B. in Biochemistry from Middlebury College and an M.D. from New York Medical College. He completed his residency in Internal Medicine at Dartmouth-Hitchcock Medical Center and his fellowship in Hematology and Oncology at the University of Chicago Medical Center.- Gregory R. Friberg，2024年9月加入BioMarin，现任执行副总裁兼首席研发官。Friberg博士负责BioMarin的发现研究、临床前、转化和临床项目，以及全球监管和医疗事务。在加入BioMarin之前，Friberg博士在生物技术公司安进工作了18年，最近担任该公司罕见病全球医疗事务副总裁。在任职安进期间，他负责推进从研究性新药申请备案到后期开发的多种药物，还担任安进血液学/肿瘤学和骨骼产品组合的全球开发主管。在开始生物制药行业的职业生涯之前，弗里伯格博士曾在芝加哥大学任教。现任美国临床肿瘤学会、美国癌症研究协会会员。弗里伯格博士拥有米德尔伯里学院的生物化学A.B.和纽约医学院的医学博士学位。他在达特茅斯-希区柯克医学中心完成了内科住院医师实习，并在芝加哥大学医学中心完成了血液学和肿瘤学研究金。
- Gregory R. Friberg,joined BioMarin in September 2024 and currently serves as Executive Vice President and Chief Research & Development Officer. Dr. Friberg is responsible for BioMarin's discovery research, preclinical, translational and clinical programs, as well as global regulatory and medical affairs. Prior to joining BioMarin, Dr. Friberg spent 18 years at Amgen, a biotechnology company, where he served most recently as Vice President, Global Medical Affairs, Rare Disease. During his time at Amgen, he was responsible for advancing multiple medicines from investigational new drug application filing through late-stage development, and also served as the head of global development for Amgen's hematology/oncology and bone portfolios. Before beginning his career in the biopharma industry, Dr. Friberg served on the faculty of the University of Chicago. He is currently a member of the American Society of Clinical Oncology and the American Association for Cancer Research. Dr. Friberg holds an A.B. in Biochemistry from Middlebury College and an M.D. from New York Medical College. He completed his residency in Internal Medicine at Dartmouth-Hitchcock Medical Center and his fellowship in Hematology and Oncology at the University of Chicago Medical Center.
- C. Greg Guyer
C. Greg Guyer，2020年5月加入BioMarin，现任执行副总裁兼首席技术官。Guyer博士负责监督拜玛林制药 Inc.的制造、工艺开发、质量、供应链、工程和分析化学部门。从2015年到2019年，Guyer博士在百时美施贵宝（BMS）担任过多个责任越来越大的职位，主要领导所有运营和生物开发。在加入BMS之前，Guyer博士曾任职于默克制药公司,1994年至2015年，在生物和制药运营、质量、监管、新兴市场战略和企业系统方面领导各种全球组织。Guyer博士目前担任乔治亚大学研究基金会的董事会成员。Guyer博士拥有美国大学分析化学博士学位、乔治亚大学化学学士学位和利哈伊大学工商管理硕士学位。
C. Greg Guyer,joined BioMarin in May 2020 and currently serves as Executive Vice President and Chief Technical Officer. Dr. Guyer is responsible for overseeing Biomarin Pharmaceutical Inc. manufacturing, process development, quality, supply chain, engineering and analytical chemistry departments. From 2015 to 2019, Dr. Guyer served in a number of positions of increasing responsibility at Bristol Myers Squibb (BMS), primarily leading all of operations and biologic development. Prior to BMS, Dr. Guyer worked for Merck & Co., Inc., from 1994 to 2015, leading various global organizations in biologic and pharmaceutical operations, quality, regulatory, emerging markets strategy and enterprise systems. Dr. Guyer currently serves on the board of the University of Georgia Research Foundation. Dr. Guyer holds a Ph.D. in Analytical Chemistry from American University, a B.S. in Chemistry from the University of Georgia, and an M.B.A. from Lehigh University.- C. Greg Guyer，2020年5月加入BioMarin，现任执行副总裁兼首席技术官。Guyer博士负责监督拜玛林制药 Inc.的制造、工艺开发、质量、供应链、工程和分析化学部门。从2015年到2019年，Guyer博士在百时美施贵宝（BMS）担任过多个责任越来越大的职位，主要领导所有运营和生物开发。在加入BMS之前，Guyer博士曾任职于默克制药公司,1994年至2015年，在生物和制药运营、质量、监管、新兴市场战略和企业系统方面领导各种全球组织。Guyer博士目前担任乔治亚大学研究基金会的董事会成员。Guyer博士拥有美国大学分析化学博士学位、乔治亚大学化学学士学位和利哈伊大学工商管理硕士学位。
- C. Greg Guyer,joined BioMarin in May 2020 and currently serves as Executive Vice President and Chief Technical Officer. Dr. Guyer is responsible for overseeing Biomarin Pharmaceutical Inc. manufacturing, process development, quality, supply chain, engineering and analytical chemistry departments. From 2015 to 2019, Dr. Guyer served in a number of positions of increasing responsibility at Bristol Myers Squibb (BMS), primarily leading all of operations and biologic development. Prior to BMS, Dr. Guyer worked for Merck & Co., Inc., from 1994 to 2015, leading various global organizations in biologic and pharmaceutical operations, quality, regulatory, emerging markets strategy and enterprise systems. Dr. Guyer currently serves on the board of the University of Georgia Research Foundation. Dr. Guyer holds a Ph.D. in Analytical Chemistry from American University, a B.S. in Chemistry from the University of Georgia, and an M.B.A. from Lehigh University.
- Cristin Hubbard
Cristin Hubbard，2024年5月加入BioMarin，现任执行副总裁兼首席商务官。她负责领导BioMarin的全球商业运营和投资组合战略。Hubbard女士在生物制药和诊断行业工作了20多年后加入了BioMarin。她最近于2023年5月至2024年3月担任制药公司罗氏制药的全球产品战略主管，负责该公司药物从开发到商业化的生命周期管理、全球商业战略和加速交付，涉及五个治疗领域。在担任这一职务之前，她曾在罗氏（Roche）和生物技术公司基因泰克（Genentech）工作了超过16年，在这两个组织的多个领导职位上任职。Hubbard女士的职业生涯始于Theravance Biopharma, Inc.的药物化学家。她拥有加州大学圣克鲁斯分校的生物化学和分子生物学学士学位。哈伯德女士还完成了加州大学伯克利分校的健康管理研究生课程，获得了哈斯商学院的MBA学位和公共卫生学院的公共卫生硕士学位。她目前担任生物技术创新组织（BIO）的董事会成员，该组织是世界上最大的生物技术倡导组织。
Cristin Hubbard,joined BioMarin in May 2024 and currently serves as Executive Vice President and Chief Commercial Officer. She is responsible for leading BioMarin's global commercial operations and portfolio strategy. Ms. Hubbard joined BioMarin following more than 20 years in the biopharmaceutical and diagnostics industries. She was most recently head of Global Product Strategy for Roche Pharmaceuticals, a pharmaceutical company, from May 2023 to March 2024, where she was responsible for lifecycle management, global commercial strategy and accelerating delivery of the company's medicines from development to commercialization, across five therapeutic areas. Prior to such role, she spent over 16 years at Roche and Genentech, a biotechnology company, serving in a number of leadership positions across both organizations. Ms. Hubbard started her career as a medicinal chemist at Theravance Biopharma, Inc. She holds a B.S. in Biochemistry and Molecular Biology from the University of California, Santa Cruz. Ms. Hubbard also completed the Graduate Program of Health Management at the University of California, Berkeley, earning an MBA from the Haas School of Business and an MPH from the School of Public Health. She currently serves on the Board of Directors of the Biotechnology Innovation Organization (BIO), the world's largest biotech advocacy organization.- Cristin Hubbard，2024年5月加入BioMarin，现任执行副总裁兼首席商务官。她负责领导BioMarin的全球商业运营和投资组合战略。Hubbard女士在生物制药和诊断行业工作了20多年后加入了BioMarin。她最近于2023年5月至2024年3月担任制药公司罗氏制药的全球产品战略主管，负责该公司药物从开发到商业化的生命周期管理、全球商业战略和加速交付，涉及五个治疗领域。在担任这一职务之前，她曾在罗氏（Roche）和生物技术公司基因泰克（Genentech）工作了超过16年，在这两个组织的多个领导职位上任职。Hubbard女士的职业生涯始于Theravance Biopharma, Inc.的药物化学家。她拥有加州大学圣克鲁斯分校的生物化学和分子生物学学士学位。哈伯德女士还完成了加州大学伯克利分校的健康管理研究生课程，获得了哈斯商学院的MBA学位和公共卫生学院的公共卫生硕士学位。她目前担任生物技术创新组织（BIO）的董事会成员，该组织是世界上最大的生物技术倡导组织。
- Cristin Hubbard,joined BioMarin in May 2024 and currently serves as Executive Vice President and Chief Commercial Officer. She is responsible for leading BioMarin's global commercial operations and portfolio strategy. Ms. Hubbard joined BioMarin following more than 20 years in the biopharmaceutical and diagnostics industries. She was most recently head of Global Product Strategy for Roche Pharmaceuticals, a pharmaceutical company, from May 2023 to March 2024, where she was responsible for lifecycle management, global commercial strategy and accelerating delivery of the company's medicines from development to commercialization, across five therapeutic areas. Prior to such role, she spent over 16 years at Roche and Genentech, a biotechnology company, serving in a number of leadership positions across both organizations. Ms. Hubbard started her career as a medicinal chemist at Theravance Biopharma, Inc. She holds a B.S. in Biochemistry and Molecular Biology from the University of California, Santa Cruz. Ms. Hubbard also completed the Graduate Program of Health Management at the University of California, Berkeley, earning an MBA from the Haas School of Business and an MPH from the School of Public Health. She currently serves on the Board of Directors of the Biotechnology Innovation Organization (BIO), the world's largest biotech advocacy organization.
- Rashmi Ramchandani
Rashmi Ramchandani于2013年8月至2022年3月期间以及自2023年2月以来一直在上市制药公司吉利德科学公司工作，在那里她担任了越来越多的会计和财务职务，最近担任副总裁、全球业务总监，此前于2021年5月至2022年3月担任副总裁、助理总监。她还曾于2022年3月至2023年1月在私营健身追踪平台公司Strava，Inc.担任副总裁兼财务总监。Ramchandani女士于2001年在德勤开始其公共会计职业生涯，随后在高乐氏公司和McKesson公司担任会计和财务职务。Ramchandani女士是注册会计师，拥有伊利诺斯州卫斯理大学会计和心理学学士学位。
Rashmi Ramchandani,has worked at Gilead Sciences, Inc., a public pharmaceutical company, from August 2013 to March 2022 and since February 2023, where she has held various accounting and finance roles of increasing responsibility, most recently as Vice President, Global Business Controller, and previously as Vice President, Assistant Controller from May 2021 to March 2022. She also served as Vice President, Controller at Strava, Inc., a private fitness tracking platform company, from March 2022 to January 2023. Ms. Ramchandani started her career in public accounting in 2001 with Deloitte and subsequently held accounting and finance roles at The Clorox Company and McKesson Corporation. Ms. Ramchandani is a CPA and holds a BA in Accounting and Psychology from Illinois Wesleyan University.- Rashmi Ramchandani于2013年8月至2022年3月期间以及自2023年2月以来一直在上市制药公司吉利德科学公司工作，在那里她担任了越来越多的会计和财务职务，最近担任副总裁、全球业务总监，此前于2021年5月至2022年3月担任副总裁、助理总监。她还曾于2022年3月至2023年1月在私营健身追踪平台公司Strava，Inc.担任副总裁兼财务总监。Ramchandani女士于2001年在德勤开始其公共会计职业生涯，随后在高乐氏公司和McKesson公司担任会计和财务职务。Ramchandani女士是注册会计师，拥有伊利诺斯州卫斯理大学会计和心理学学士学位。
- Rashmi Ramchandani,has worked at Gilead Sciences, Inc., a public pharmaceutical company, from August 2013 to March 2022 and since February 2023, where she has held various accounting and finance roles of increasing responsibility, most recently as Vice President, Global Business Controller, and previously as Vice President, Assistant Controller from May 2021 to March 2022. She also served as Vice President, Controller at Strava, Inc., a private fitness tracking platform company, from March 2022 to January 2023. Ms. Ramchandani started her career in public accounting in 2001 with Deloitte and subsequently held accounting and finance roles at The Clorox Company and McKesson Corporation. Ms. Ramchandani is a CPA and holds a BA in Accounting and Psychology from Illinois Wesleyan University.
- G. Eric Davis
G. Eric Davis， 2004年3月加入BioMarin，现任高级副总裁、总法律顾问和秘书。从2004年到2005年12月他担任副总裁、总法律顾问和秘书。从2000年到2004年他担任普衡律师事务所（前身是保罗，黑斯廷斯，衡律师事务所）旧金山办事处职员，任职于公司全国安全实践委员会。他代表公开上市公司、私人公司、资本投资银行公司处理大范围企业安全事务、 兼并和收购、战略联盟事宜及与知识产权有关的商业交易。他的经历非常丰富，包括生物科技和生命科学行业。他持有加利佛尼亚大学伯克利分校政治经济学学士学位以及旧金山大学法学院法律博士学位。
G. Eric Davis,joined BioMarin in March 2004 and currently serves as Executive Vice President, Chief Legal Officer and Secretary. From March 2016 to March 2022, Mr. Davis served as Biomarin Pharmaceutical Inc. Executive Vice President, General Counsel and Secretary, from March 2005 to March 2016, Mr. Davis served as Biomarin Pharmaceutical Inc. Senior Vice President, General Counsel and Secretary and from 2004 to December 2005, Mr. Davis served as Biomarin Pharmaceutical Inc. Vice President, General Counsel and Secretary. From 2000 to 2004, Mr. Davis worked in the San Francisco office of Paul Hastings LLP (formerly Paul, Hastings, Janofsky & Walker LLP), where he served on the firm's national securities practice committee. Mr. Davis has represented public and private companies and venture capital and investment banking firms in a wide range of corporate and securities matters, mergers and acquisitions, strategic alliance matters, and intellectual property-related business transactions. His experience involves a variety of industries, including biotechnology and life sciences. Mr. Davis holds a B.A. in Political Economy from the University of California, Berkeley, and a J.D. from the University of San Francisco School of Law.- G. Eric Davis， 2004年3月加入BioMarin，现任高级副总裁、总法律顾问和秘书。从2004年到2005年12月他担任副总裁、总法律顾问和秘书。从2000年到2004年他担任普衡律师事务所（前身是保罗，黑斯廷斯，衡律师事务所）旧金山办事处职员，任职于公司全国安全实践委员会。他代表公开上市公司、私人公司、资本投资银行公司处理大范围企业安全事务、 兼并和收购、战略联盟事宜及与知识产权有关的商业交易。他的经历非常丰富，包括生物科技和生命科学行业。他持有加利佛尼亚大学伯克利分校政治经济学学士学位以及旧金山大学法学院法律博士学位。
- G. Eric Davis,joined BioMarin in March 2004 and currently serves as Executive Vice President, Chief Legal Officer and Secretary. From March 2016 to March 2022, Mr. Davis served as Biomarin Pharmaceutical Inc. Executive Vice President, General Counsel and Secretary, from March 2005 to March 2016, Mr. Davis served as Biomarin Pharmaceutical Inc. Senior Vice President, General Counsel and Secretary and from 2004 to December 2005, Mr. Davis served as Biomarin Pharmaceutical Inc. Vice President, General Counsel and Secretary. From 2000 to 2004, Mr. Davis worked in the San Francisco office of Paul Hastings LLP (formerly Paul, Hastings, Janofsky & Walker LLP), where he served on the firm's national securities practice committee. Mr. Davis has represented public and private companies and venture capital and investment banking firms in a wide range of corporate and securities matters, mergers and acquisitions, strategic alliance matters, and intellectual property-related business transactions. His experience involves a variety of industries, including biotechnology and life sciences. Mr. Davis holds a B.A. in Political Economy from the University of California, Berkeley, and a J.D. from the University of San Francisco School of Law.
- Brian R. Mueller
Brian R. Mueller， 2002年12月加入BioMarin，现任集团副总裁和公司总监。自2011年3月起担任公司首席会计官。从2009年3月到2014年3月他担任副总裁和公司总监；从2007年7月到2009年3月担任高级董事和企业总监。2002年加入BioMarin之前，他在毕马威律师事务所任职，担任律所审计实践处高级主管。2002年6月安永会计师事务所停止运营，他开始加入毕马威律师事务所。之前他曾在安永会计师事务所工作7年，担任律所审计和业务顾问服务实践处成员。他持有伊利诺斯大学（位于伊利诺斯迪卡尔布）会计学士学位并且是美国注册会计师协会成员。
Brian R. Mueller,joined BioMarin in December 2002, currently serves as Executive Vice President and Chief Financial Officer and from March 2011 to June 2020 he served as Chief Accounting Officer. Prior to his role as Chief Accounting Officer, Mr. Mueller served in accounting roles of increasing responsibility, including Corporate Controller. Prior to joining BioMarin in 2002, Mr. Mueller worked for KPMG as a senior manager in the firm's audit practice. Mr. Mueller joined KPMG after Arthur Andersen LLP ceased operations in June 2002, prior to which he spent seven years with Arthur Andersen LLP in the firm's audit and business advisory services practice. Mr. Mueller holds a B.S. in Accountancy from Northern Illinois University in DeKalb, Illinois, and is a member of the American Institute of Certified Public Accountants.- Brian R. Mueller， 2002年12月加入BioMarin，现任集团副总裁和公司总监。自2011年3月起担任公司首席会计官。从2009年3月到2014年3月他担任副总裁和公司总监；从2007年7月到2009年3月担任高级董事和企业总监。2002年加入BioMarin之前，他在毕马威律师事务所任职，担任律所审计实践处高级主管。2002年6月安永会计师事务所停止运营，他开始加入毕马威律师事务所。之前他曾在安永会计师事务所工作7年，担任律所审计和业务顾问服务实践处成员。他持有伊利诺斯大学（位于伊利诺斯迪卡尔布）会计学士学位并且是美国注册会计师协会成员。
- Brian R. Mueller,joined BioMarin in December 2002, currently serves as Executive Vice President and Chief Financial Officer and from March 2011 to June 2020 he served as Chief Accounting Officer. Prior to his role as Chief Accounting Officer, Mr. Mueller served in accounting roles of increasing responsibility, including Corporate Controller. Prior to joining BioMarin in 2002, Mr. Mueller worked for KPMG as a senior manager in the firm's audit practice. Mr. Mueller joined KPMG after Arthur Andersen LLP ceased operations in June 2002, prior to which he spent seven years with Arthur Andersen LLP in the firm's audit and business advisory services practice. Mr. Mueller holds a B.S. in Accountancy from Northern Illinois University in DeKalb, Illinois, and is a member of the American Institute of Certified Public Accountants.